1 / 38

Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC

Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC. Why worry about Pharmacokinetics (PK) and Drug – Drug Interactions (DDIs) in managing HCV patients?. Interaction due to Enzyme Inhibition : Increased systemic exposure.

jock
Télécharger la présentation

Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC

  2. Why worry about Pharmacokinetics (PK) and Drug – Drug Interactions (DDIs) in managing HCV patients?

  3. Interaction due to Enzyme Inhibition:Increased systemic exposure

  4. Interaction due to Enzyme Induction: Decreased systemic exposure

  5. The importance of Cytochrome P450 (CYP) enzymes

  6. Drugs can be metabolised in the Gastrointestinal tract and Liver

  7. Drugs can be transported in the Gastrointestinal tract and Liver

  8. Understanding the disposition of the DAAs

  9. Telaprevir DDIs

  10. Telaprevir increases exposure to CYP3A substrates: Perpetrator

  11. Telaprevir increases exposure to CYP3A substrates

  12. Telaprevir decreases exposure to other CYP substrates

  13. Telaprevir decreases total but not unbound methadone concentrations.

  14. Enzyme inducing agents reduce telaprevir exposure: Victim

  15. Interactions with Boosted PIs

  16. Telaprevir: DDIs with HIV antiretrovirals

  17. Key CROI abstract

  18. Boceprevir DDIs

  19. Boceprevir increases exposure to CYP3A substrates

  20. Boceprevir decreases exposure to other CYP substrates

  21. Boceprevir exposure is decreased by efavirenz

  22. Interaction of Boceprevir and Boosted HIV PIs

  23. Boceprevir does not alter the PK of Raltegravir

  24. Key CROI abstract

  25. DAA Clinical Pharmacology

  26. Contraindications with telaprevir and boceprevir

  27. Drug Survey: Outline

  28. Management of Drug-Drug Interactions

  29. Disposition of Antidepressants

  30. DAAs and Lipid Lowering Agents

  31. Implications for clinical practice

  32. TMC435 (Simeprivir)

  33. TMC435 (Simeprivir) Interactions

  34. BMS-790052

  35. DAA clinical pharmacology: conclusions

  36. Thank you

More Related